Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18311075 | SONOGENETIC MODULATION OF CELLS EXPRESSING BACTERIALLY-DERIVED MECHANOSENSITIVE PROTEINS | Non-Final OA | The Regents of the University of California |
| 17633912 | Immunomodulatory Compounds | Non-Final OA | The Regents of the University of California |
| 17905520 | MULTISPECIFIC BINDING PROTEINS AND METHODS OF DEVELOPING THE SAME | Non-Final OA | Eli Lilly and Company |
| 18333223 | TOPICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTIBODIES AND FRAGMENTS THEREOF | Final Rejection | University College London |
| 18754670 | NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOF | Final Rejection | ARAVAX PTY LTD |
| 17797540 | METHODS FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18592425 | ANTI-PD-L1 AND IL-2 CYTOKINES | Non-Final OA | KYMAB LIMITED |
| 18432126 | VARIABLE REGIONS FOR NKP46 BINDING PROTEINS | Final Rejection | INNATE PHARMA |
| 18543874 | ANTI-KIT ANTIBODIES AND USES THEREOF | Non-Final OA | Celldex Therapeutics, Inc. |
| 18310649 | KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS | Non-Final OA | Fred Hutchinson Cancer Center |
| 18452346 | FCRN ANTIBODIES AND METHODS OF USE THEREOF | Final Rejection | Momenta Pharmaceuticals, Inc. |
| 18334820 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | Non-Final OA | BioNTech US Inc. |
| 18034134 | ANTI-SARS-COV-2 ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | Adaptive Biotechnologies Corporation |
| 18028039 | PHARMACEUTICAL COMPOSITION | Non-Final OA | EISAI R&D MANAGEMENT CO., LTD. |
| 18006591 | FUSION PROTEIN AND USE THEREOF | Non-Final OA | SUPERMAB (BEIJING) BIOTECH CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy